MAGNOFLORINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H24NO4
Molecular Weight	342.4089
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	1

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12CC3=C(C(O)=C(OC)C=C3)C4=C1C(CC[N+]2(C)C)=CC(OC)=C4O

InChI

InChIKey=YLRXAIKMLINXQY-ZDUSSCGKSA-O

InChI=1S/C20H23NO4/c1-21(2)8-7-12-10-15(25-4)20(23)18-16(12)13(21)9-11-5-6-14(24-3)19(22)17(11)18/h5-6,10,13H,7-9H2,1-4H3,(H-,22,23)/p+1/t13-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C20H23NO4
Molecular Weight	341.4009
Charge	0
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23456265 | https://www.ncbi.nlm.nih.gov/pubmed/25840917

Magnoflorine is a chemical compound isolated from the rhizome of Sinomenium acutum and from Pachygone ovata. Magnoﬂorine was shown to suppress the induction phase of the cellular immune response, and assigned as noncytotoxic to various human cancer cell lines. In addition, it was shown that Sinomeni Caulis et Rhizoma has sedative and anxiolytic effects, probably mediated by magnoflorine through a GABAergic mechanism of action. Moreover, magnoflorine can protect the erythrocyte membrane from LPC-induced damage, which was demonstrated in experiments on rat erythrocytes. This protective effect is mediated by some mechanism other than prevention of micelle formation or protection of the erythrocyte membrane against osmotic imbalance.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Anxiety 267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23456265	Primary		Not Provided 504	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Magnoflorine in Caltha palustris L].	1963 Apr 12	13938623
[PHARMACOLOGICAL STUDIES ON MAGNOFLORINE, A HYPOTENSIVE PRINCIPLE FROM TU QING MU XIANG].	1964 Jan	14125837
[MAGNOFLORINE IN OPIUM].	1964 Oct 16	14230285
The involvement of magnoflorine in the sedative and anxiolytic effects of Sinomeni Caulis et Rhizoma in mice.	2013 Oct	23456265

Sample Use Guides

In Vivo Use Guide

in mice: 70% ethanol extract of Sinomeni Caulis et Rhizoma (magnoflorine is a component of this extract) was orally administered to mice at dosages of 25, 50, 100, 200 or 400 mg/kg.

Route of Administration: Oral

In Vitro Use Guide

The effective action of magnoﬂorine on the ability of HDL to protect LDL from Cu2+ (0.5 uM)-mediated oxidation was evaluated by the measurement of the peroxide value. The oxidized HDL (HDL-0), which was prepared from exposure of HDL to Cu2+ (5 uM) in the absence of magnoﬂorine, expressed a slight protection (28.5%), while native HDL was highly effective (68.8%) in protecting LDL from the oxidation. The inclusion of magnoﬂorine/Cu2+ oxidized HDL preparations (HDL-1.0, -2.0, -5.0, -10.0) decreased lipid oxidation of LDL progressively with increasing concentration of magnoﬂorine (1.0, 2.0, 5.0, 10.0 uM). It is suggested that the ability of magnoﬂorine/Cu2+ oxidized HDL in preventing LDL oxidation maybe related to the oxidation state of HDL after pre-incubation.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:50:36 GMT 2023` Edited by `admin` on `Fri Dec 15 17:50:36 GMT 2023`
Record UNII	NI8K6962K4
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MAGNOFLORINE

Common Name

English

MAGNOFLORINE [MI]

Common Name

English

ESCHOLINE

Common Name

English

.ALPHA.-MAGNOFLORINE

Common Name

English

THALICTRINE

Common Name

English

ESCHOLIN

Common Name

English

(6AS)-5,6,6A,7-TETRAHYDRO-1,11-DIHYDROXY-2,10-DIMETHOXY-6,6-DIMETHYL-4H-DIBENZO(DE,G)QUINOLINIUM

Common Name

English

Code System Code Type Description

FDA UNII

NI8K6962K4